Home › Esophageal Adenocarcinoma › New York › The Bronx
Esophageal Adenocarcinoma clinical trials in The Bronx, NY
3 studies for Esophageal Adenocarcinoma are looking for participants at sites in and around The Bronx (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
RecruitingPhase 3
- Montefiore Medical Center-Einstein Campus, The Bronx
- Montefiore Medical Center-Weiler Hospital, The Bronx
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RecruitingPhase 3
- Research Site, The Bronx
- Research Site, The Bronx
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RecruitingPhase 1
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, The Bronx
Esophageal Adenocarcinoma trials in other cities
- New York City, NY18 studies
- Boston, MA13 studies
- Houston, TX12 studies
- Arlington, VA11 studies
- Nashville, TN11 studies
- Durham, NC10 studies
- Baldwin Park, CA9 studies
- St. Louis, MO9 studies
- Rochester, MN9 studies
- Jacksonville, FL9 studies
- Queens, NY9 studies
- Los Angeles, CA9 studies
Other studies in The Bronx
- Non-Small Cell Lung Cancer25 studies
- Breast Cancer17 studies
- Acute Myeloid Leukemia15 studies
- Lung Cancer13 studies
- Cancer (all types)12 studies
- Cardiovascular Disease12 studies
- Heart Failure11 studies
- Prostate Cancer11 studies
- Metastatic Cancer9 studies
- Colorectal Cancer9 studies
- Head and Neck Squamous Cell Carcinoma9 studies
- Myelodysplastic Syndromes9 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.